ArticleJournal of biochemical and molecular toxicology2026
Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy: Elucidating How SPARC Shapes the Tumor Microenvironment and Undermines the Response to Immune Checkpoint Inhibition.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) frequently demonstrates resistance to immunotherapeutic interventions, a phenomenon largely linked to mechanisms of immune escape. Among the modulators of the tumor microenvironment, SPARC (Secreted Protein Acidic and Rich in Cysteine), a matricellular glycoprotein, has been associated with diverse oncogenic processes in multiple cancer types. However, the contribution of SPARC to immune regulation through CD276 signaling remains insufficiently characterized. To clarify this mechanism, we employed the murine Hepa1-6 hepatoma cell line established from C57BL/6 mice. Functional studies were carried out by genetically altering the expression of SPARC and CD276, followed by comprehensive assessments including Western blot analysis, polymerase chain reaction, flow cytometry, and in vivo tumorigenicity assays. Overexpression of SPARC in HCC cells led to increased CD276 levels through activation of the p65/c-Myc axis, which also promoted cancer cell stemness. This upregulation impaired the response to immune checkpoint blockade (ICB) therapy, as evidenced by reduced infiltration and activation of CD8 + T cells within the tumor microenvironment. Additionally, increased SPARC-induced CD276 expression diminished T-cell activation and proliferation, marked by decreased IFN-γ production and reduced phosphorylation of ZAP70, a key T-cell signaling molecule. Our findings underscore the critical role of SPARC in upregulating CD276 in HCC, which contributes to immune suppression and resistance to ICB therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.